Carprogesic 20 mg Tablets for Dogs

Country: United Kingdom

Language: English

Source: VMD (Veterinary Medicines Directorate)

Active ingredient:

Carprofen

Available from:

Norbrook Laboratories Limited

ATC code:

QM01AE91

INN (International Name):

Carprofen

Pharmaceutical form:

Tablet

Prescription type:

POM-V - Prescription Only Medicine – Veterinarian

Therapeutic group:

Dogs

Therapeutic area:

Anti Inflammatory NSAID

Authorization status:

Expired

Authorization date:

2006-04-12

Summary of Product characteristics

Revised: October 2012
AN: 00797/2012
Page 1 of 5
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Carprogesic 20mg Tablets for Dogs (UK, France)
Carprieve 20mg Tablets for Dogs (Germany)
Norocarp 20mg Tablets for Dogs (Belgium, Luxembourg)
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains:
Active Ingredient:
Carprofen
20 mg
Excipients:
For a full list of excipients see Section 6.1
3.
PHARMACEUTICAL FORM
Tablet
A white/off white circular tablet of 8 mm diameter, 20 embossed on one
side and a
single breakline on the other side.
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES:
Dogs
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES:
In the dog:
Reduction of inflammation and pain caused by musculo-skeletal
disorders and
degenerative
joint
disease.
As
a
follow
up
to
parenteral
analgesia
in
the
management of post-operative pain.
4.3
CONTRAINDICATIONS:
Do not use in cats.
Do not use in puppies less than 4 months of age.
Do not use in case of hypersensitivity to active substance or to any
of the
excipients.
Do not use in dogs suffering from cardiac, hepatic or renal disease,
where there is a
possibility of gastrointestinal ulceration or bleeding, or where there
is evidence of a
blood dyscrasia.
Refer to section 4.7
4.4
SPECIAL WARNINGS FOR EACH TARGET SPECIES:
Refer to Sections 4.3 and 4.5.
Revised: October 2012
AN: 00797/2012
Page 2 of 5
4.5
SPECIAL PRECAUTIONS FOR USE:
i.
Special precautions for use in animals
Use in aged dogs may involve additional risk.
If
such
a
use
cannot
be
avoided,
dogs
may
require
careful
clinical
management.
Avoid use in any dehydrated, hypovolaemic or hypotensive dog, as there
is a
potential risk of increased renal toxicity.
NSAIDs can cause inhibition of phagocytosis and hence in the treatment
of
inflammatory
conditions
associated
with
bacterial
infection,
appropriate
concurrent antimicrobial therapy should be instigated.
Some NSAIDs may be highly bound to plasma proteins and compete with
other highly bound drugs which can lead to toxic effects.
ii.